Lumiracoxib – 100 mg

Brand:
Cayman
CAS:
220991-20-8
Storage:
-20
UN-No:
Non-Hazardous - /

Lumiracoxib is a selective inhibitor of COX-2 with IC50 values of 0.13 and 67 µM for COX-2 and COX-1, respectively, in isolated human whole blood.{45516} It reduces increases in the levels of prostaglandin E2 (PGE2; Item No. 14010) induced by IL-1β in human dermal fibroblasts (IC50 = 0.14 µM), as well as in LPS-stimulated RAW 264.7 cells when used at concentrations ranging from 1 to 100 µM.{45516},{45517} Lumiracoxib (3 and 10 mg/kg) also decreases LPS-induced increases in the levels of PGE2 in a rat model of air pouch inflammation.{45518} It reduces M. tuberculosis-induced increases in hind paw volume and the radiological and histopathological severity of arthritic lesions in a rat model of chronic arthritis when administered at a dose of 2 mg/kg.{45516}  

 

Available on backorder

SKU: 27645 - 100 mg Category:

Description

A selective inhibitor of COX-2 over COX-1 (IC50s = 0.13 and 67 µM, respectively); reduces increases in the levels of PGE2 induced by IL-1β in human dermal fibroblasts (IC50 = 0.14 µM), as well as in LPS-stimulated RAW 264.7 cells at 1-100 µM; decreases LPS-induced increases in the levels of PGE2 in a rat model of air pouch inflammation at 3 and 10 mg/kg; reduces M. tuberculosis-induced increases in hind paw volume and the radiological and histopathological severity of arthritic lesions in a rat model of chronic arthritis at 2 mg/kg


Formal name: 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl-benzeneacetic acid

Synonyms:  COX 189

Molecular weight: 293.7

CAS: 220991-20-8

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Cyclooxygenases||Research Area|Immunology & Inflammation|Autoimmunity|Rheumatoid Arthritis||Research Area|Immunology & Inflammation|Inflammatory Lipid Mediators|Prostaglandins||Research Area|Immunology & Inflammation|Innate Immunity